3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
6
Recruiting
5
Active not recruiting
4
Not yet recruiting
3
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
6
Hematologic Neoplasms
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colorectal Neoplasms
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Motor Activity
2
Head and Neck Neoplasms
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Anxiety Disorders
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Interventions
pembrolizumab
29
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
Standard of Care
×
Clear all
NCT01468623
2023-07-19
PROFUSE
Myriad Genetic Laboratories, Inc.
Phase 4
Terminated
51 enrolled